A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway

Seiichi Hosaka, Keisuke Horiuchi, Masaki Yoda, Turrent Robert Nakayama, Takahide Tohmonda, Michiro Susa, Masaya Nakamura, Kazuhiro Chiba, Yoshiaki Toyama, Hideo Morioka

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Synovial sarcoma is an aggressive soft tissue sarcoma with only a modest response to conventional cytotoxic agents. In the present study, we evaluated the potential antitumor effects of a novel anti-angiogenesis agent, pazopanib, against synovial sarcoma cells. We found that pazopanib directly inhibited the growth of synovial sarcoma cells by inducing G1 arrest. Multiplex analyses revealed that the PI3K-AKT pathway was highly suppressed in pazopanib-sensitive synovial sarcoma cells. Furthermore, administration of pazopanib highly suppressed the tumor growth in a xenograft model. Taken together, these results suggest pazopanib as a possible agent against synovial sarcoma and may warrant further clinical studies.

Original languageEnglish
Pages (from-to)1493-1498
Number of pages6
JournalJournal of Orthopaedic Research
Volume30
Issue number9
DOIs
Publication statusPublished - 2012 Sep

Fingerprint

Synovial Sarcoma
Phosphatidylinositol 3-Kinases
Phosphotransferases
Growth
Cytotoxins
Heterografts
Sarcoma
pazopanib
Neoplasms

Keywords

  • molecular targeted therapy
  • pazopanib
  • PI3K-AKT pathway
  • synovial sarcoma

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway. / Hosaka, Seiichi; Horiuchi, Keisuke; Yoda, Masaki; Nakayama, Turrent Robert; Tohmonda, Takahide; Susa, Michiro; Nakamura, Masaya; Chiba, Kazuhiro; Toyama, Yoshiaki; Morioka, Hideo.

In: Journal of Orthopaedic Research, Vol. 30, No. 9, 09.2012, p. 1493-1498.

Research output: Contribution to journalArticle

Hosaka, Seiichi ; Horiuchi, Keisuke ; Yoda, Masaki ; Nakayama, Turrent Robert ; Tohmonda, Takahide ; Susa, Michiro ; Nakamura, Masaya ; Chiba, Kazuhiro ; Toyama, Yoshiaki ; Morioka, Hideo. / A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway. In: Journal of Orthopaedic Research. 2012 ; Vol. 30, No. 9. pp. 1493-1498.
@article{6562ec806bd14cae8c55b665a6223d4d,
title = "A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway",
abstract = "Synovial sarcoma is an aggressive soft tissue sarcoma with only a modest response to conventional cytotoxic agents. In the present study, we evaluated the potential antitumor effects of a novel anti-angiogenesis agent, pazopanib, against synovial sarcoma cells. We found that pazopanib directly inhibited the growth of synovial sarcoma cells by inducing G1 arrest. Multiplex analyses revealed that the PI3K-AKT pathway was highly suppressed in pazopanib-sensitive synovial sarcoma cells. Furthermore, administration of pazopanib highly suppressed the tumor growth in a xenograft model. Taken together, these results suggest pazopanib as a possible agent against synovial sarcoma and may warrant further clinical studies.",
keywords = "molecular targeted therapy, pazopanib, PI3K-AKT pathway, synovial sarcoma",
author = "Seiichi Hosaka and Keisuke Horiuchi and Masaki Yoda and Nakayama, {Turrent Robert} and Takahide Tohmonda and Michiro Susa and Masaya Nakamura and Kazuhiro Chiba and Yoshiaki Toyama and Hideo Morioka",
year = "2012",
month = "9",
doi = "10.1002/jor.22091",
language = "English",
volume = "30",
pages = "1493--1498",
journal = "Journal of Orthopaedic Research",
issn = "0736-0266",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway

AU - Hosaka, Seiichi

AU - Horiuchi, Keisuke

AU - Yoda, Masaki

AU - Nakayama, Turrent Robert

AU - Tohmonda, Takahide

AU - Susa, Michiro

AU - Nakamura, Masaya

AU - Chiba, Kazuhiro

AU - Toyama, Yoshiaki

AU - Morioka, Hideo

PY - 2012/9

Y1 - 2012/9

N2 - Synovial sarcoma is an aggressive soft tissue sarcoma with only a modest response to conventional cytotoxic agents. In the present study, we evaluated the potential antitumor effects of a novel anti-angiogenesis agent, pazopanib, against synovial sarcoma cells. We found that pazopanib directly inhibited the growth of synovial sarcoma cells by inducing G1 arrest. Multiplex analyses revealed that the PI3K-AKT pathway was highly suppressed in pazopanib-sensitive synovial sarcoma cells. Furthermore, administration of pazopanib highly suppressed the tumor growth in a xenograft model. Taken together, these results suggest pazopanib as a possible agent against synovial sarcoma and may warrant further clinical studies.

AB - Synovial sarcoma is an aggressive soft tissue sarcoma with only a modest response to conventional cytotoxic agents. In the present study, we evaluated the potential antitumor effects of a novel anti-angiogenesis agent, pazopanib, against synovial sarcoma cells. We found that pazopanib directly inhibited the growth of synovial sarcoma cells by inducing G1 arrest. Multiplex analyses revealed that the PI3K-AKT pathway was highly suppressed in pazopanib-sensitive synovial sarcoma cells. Furthermore, administration of pazopanib highly suppressed the tumor growth in a xenograft model. Taken together, these results suggest pazopanib as a possible agent against synovial sarcoma and may warrant further clinical studies.

KW - molecular targeted therapy

KW - pazopanib

KW - PI3K-AKT pathway

KW - synovial sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84863836492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863836492&partnerID=8YFLogxK

U2 - 10.1002/jor.22091

DO - 10.1002/jor.22091

M3 - Article

VL - 30

SP - 1493

EP - 1498

JO - Journal of Orthopaedic Research

JF - Journal of Orthopaedic Research

SN - 0736-0266

IS - 9

ER -